Gorschlüter M, Ziske C, Glasmacher A, Schmidt-Wolf I G
Department of Internal Medicine I, University of Bonn, Sigmund-Freud-Strasse 25, 53105 Bonn, Germany.
Clin Cancer Res. 2001 Aug;7(8):2195-204.
Multiple myeloma is still an incurable, lethal disease for the vast majority of patients. Myeloablative chemotherapy combined with autologous or allogeneic hematopoietic stem cell transplantation only partially met the great expectations initially set in its efficacy and is associated with a high level of toxicity. However, the considerable progress in understanding the biology of multiple myeloma led to the development of promising molecular therapies. Numerous immunotherapy-based approaches are currently evaluated in clinical trials. Moreover, remarkable progress has been achieved in gene therapy during the last decade, and the repertoire of gene transfer techniques can be expected to improve continuously. Gene transfer is increasingly applied in biological therapies in multiple myeloma. This article reviews the currently applied clinical and laboratory strategies to augment the efficacy of immunotherapy in multiple myeloma and aims to define its perspectives in multimodality treatment of multiple myeloma.
对于绝大多数患者而言，多发性骨髓瘤仍然是一种无法治愈的致命疾病。清髓性化疗联合自体或异基因造血干细胞移植仅部分达到了最初对其疗效所寄予的厚望，并且伴有高度毒性。然而，在对多发性骨髓瘤生物学的理解方面取得的显著进展促成了有前景的分子疗法的发展。目前，众多基于免疫疗法的方法正在临床试验中接受评估。此外，在过去十年中基因治疗取得了显著进展，基因转移技术有望持续改进。基因转移在多发性骨髓瘤的生物治疗中应用越来越广泛。本文综述了目前为提高多发性骨髓瘤免疫治疗疗效而应用的临床和实验室策略，并旨在明确其在多发性骨髓瘤多模式治疗中的前景。
